Perspective - Journal of Cardiovascular Medicine and Therapeutics (2023) Volume 7, Issue 4

Novel biomarkers for early detection and risk stratification in cardiovascular disorders

Cigdem Yucel ^*

Department of Biomedical and Clinical Sciences ,University of Milan, Milano, Italy.

*Corresponding Author:

Cigdem Yucel
Department of Biomedical and Clinical Sciences ,University of Milan, Milano, Italy
E-mail: yucel.ci.122@yc.edu

Received: 31-July-2023, Manuscript No. AACMT-23-108759; Editor assigned: 01-Aug-2023, PreQC No. AACMT-23-108759; Reviewed:16-Aug-2023, QC No. AACMT-23-108759; Revised:19-Aug-2023, Manuscript No. AACMT-23-108759(R); Published:30-Aug-2023, DOI:10.35841/ aacmt -7.4.157

Citation: : Yucel C. Novel biomarkers for early detection and risk stratification in cardiovascular disorders. J Cardiovasc Med Ther. 2023; 7(4):157

Introduction

Cardiovascular disorders remain a significant global health burden, contributing to a substantial number of deaths and disabilities each year. Timely detection and accurate risk stratification are crucial for effective management and prevention of cardiovascular diseases (CVDs). In recent years, there has been an increasing focus on identifying novel biomarkers that can aid in the early detection and risk assessment of CVDs. These biomarkers offer promising insights into disease pathophysiology and provide valuable information for personalized treatment strategies. This article delves into the latest advancements in the field of cardiovascular biomarkers and their potential to revolutionize early detection and risk stratification for various cardiovascular disorders [1].

Early detection plays a pivotal role in managing and treating cardiovascular disorders. Traditionally, the diagnosis of CVDs relied on established risk factors and clinical symptoms, which often manifested at later stages of the disease. However, these methods may not be sensitive enough to identify individuals with subclinical disease or those at higher risk of developing CVDs. Novel biomarkers offer a unique opportunity to detect cardiovascular abnormalities before overt clinical symptoms occur, enabling early intervention and better patient outcomes [2].

Advancements in omics technologies, including genomics, proteomics, and metabolomics, have led to the discovery of a myriad of potential biomarkers associated with cardiovascular disorders. For instance, high-sensitivity cardiac troponins, which are more sensitive than traditional troponin assays, allow for the detection of minor myocardial damage and the diagnosis of acute coronary syndromes earlier. Similarly, microRNAs have shown promise as non-invasive biomarkers for heart failure, providing valuable information about cardiac remodeling and dysfunction. Besides, novel imaging techniques like coronary artery calcification scoring and cardiac MRI have emerged as potential tools for detecting atherosclerosis and cardiac structural abnormalities [3].

In addition to early detection, biomarkers also play a crucial role in risk stratification, helping to identify individuals at higher risk of developing CVDs. Integrating biomarker data with traditional risk assessment tools, such as the Framingham Risk Score or the ASCVD Risk Calculator, can enhance risk prediction accuracy. Several studies have demonstrated the utility of combining multiple biomarkers, including high-sensitivity C-reactive protein (hs-CRP), brain natriuretic peptide (BNP), and lipoprotein(a) [Lp(a)], to better assess the risk of cardiovascular events. These innovative risk stratification approaches hold promise for more targeted and effective preventive interventions [4].

While the discovery of novel biomarkers for cardiovascular disorders is promising, their translation into routine clinical practice faces several challenges. Standardization, reproducibility, and validation of biomarker assays are essential to ensure their accuracy and clinical utility. Moreover, the integration of biomarker data into existing risk prediction models necessitates careful validation and implementation in diverse patient populations. Additionally, the ethical considerations surrounding the use of biomarkers, such as privacy and potential discrimination, must be carefully addressed [5].

conclusion

Novel biomarkers have emerged as potential game-changers in the early detection and risk stratification of cardiovascular disorders. These innovative tools offer valuable insights into disease pathophysiology and can help identify high-risk individuals even before clinical symptoms manifest. However, successful integration into routine clinical practice requires addressing technical, logistical, and ethical challenges. As research continues to progress, the use of biomarkers in cardiovascular care holds immense promise for more precise, personalized, and effective preventive strategies, ultimately contributing to a reduction in the global burden of cardiovascular diseases.

References

1. McCann CJ, Glover BM, Menown IB, et al. Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur Heart J. 2008;29(23):2843-50.

Indexed at, Google Scholar, Cross Ref

2. Dinh W, Nickl W, Füth R, et al. High sensitive troponin T and heart fatty acid binding protein: Novel biomarker in heart failure with normal ejection fraction?: A cross-sectional study. BMC Cardiovasc Disord. 2011;11:1-9.

Indexed at, Google Scholar, Cross Ref

3. Marcovecchio ML. Importance of identifying novel biomarkers of microvascular damage in type 1 diabetes. Mol Diagn Ther. 2020;24(5):507-15.

Indexed at, Google Scholar, Cross Ref

4. Kosmopoulos M, Paschou SA, Grapsa J, et al. The emerging role of bone markers in diagnosis and risk stratification of patients with coronary artery disease. Angiol. 2019;70(8):690-700.

Indexed at, Google Scholar, Cross Ref

5. Deddens JC, Colijn JM, Oerlemans MI, et al. Circulating microRNAs as novel biomarkers for the early diagnosis of acute coronary syndrome. J Cardiovasc Transl Res. 2013;6:884-98.

Indexed at, Google Scholar, Cross Ref